9.78
-0.36(-3.55%)
Currency In USD
| Previous Close | 10.14 |
| Open | 9.89 |
| Day High | 9.99 |
| Day Low | 9.49 |
| 52-Week High | 29.56 |
| 52-Week Low | 8.18 |
| Volume | 640,890 |
| Average Volume | 1M |
| Market Cap | 745.58M |
| PE | -3.51 |
| EPS | -2.79 |
| Moving Average 50 Days | 11.16 |
| Moving Average 200 Days | 18.95 |
| Change | -0.36 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $514.47 as of May 22, 2025 at a share price of $9.78. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $967.36 as of May 22, 2025 at a share price of $9.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
GlobeNewswire Inc.
May 15, 2025 11:00 AM GMT
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announc
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
GlobeNewswire Inc.
May 14, 2025 1:30 PM GMT
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announc
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs
GlobeNewswire Inc.
Apr 28, 2025 8:00 PM GMT
Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many tar